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Background: Thromboembolism (TE) and infection are two common complications of central venous line (CVL).
Thrombotic CVL-dysfunction is a common, yet less studied, complication of CVL. Two retrospective studies have
reported significant association of CVL-dysfunction and TE. Recent studies indicate association of CVL-related small
clot with infection. Infection is the most common cause of non-cancer related mortality in children with cancer. We
and others have shown reduced overall survival (OS) in children with cancer and CVL-dysfunction compared to
those without CVL-dysfunction. Despite these observations, to date there are no prospective studies to evaluate the
clinical significance of CVL-dysfunction and it’s impact on the development of TE, infection, or outcome of children
with cancer.
Study design: This is a prospective, analytical cohort study conducted at five tertiary care pediatric oncology
centers in Ontario. Children (≤ 18 years of age) with non-central nervous system cancers and CVL will be eligible
for the study. Primary outcome measure is symptomatic TE and secondary outcomes are infection, recurrence of
cancer and death due to any cause. Data will be analyzed using regression analyses.
Discussion: The overall objective is to delineate the relationship between CVL-dysfunction, infection and TE. The
primary aim is to evaluate the role of CVL-dysfunction as a predictor of symptomatic TE in children with cancer. We
hypothesize that children with CVL-dysfunction have activation of the coagulation system resulting in an increased
risk of symptomatic TE. The secondary aims are to study the impact of CVL-dysfunction on the rate of infection and
the survival [OS and event free survival (EFS)] of children with cancer. We postulate that patients with CVL-
dysfunction have an occult CVL-related clot which acts as a microbial focus with resultant increased risk of
infection. Further, CVL-dysfunction by itself or in combination with associated complications may cause therapy
delays resulting in adverse outcome.
This study will help to identify children at high risk for TE and infection. Based on the study results, we will design
randomized controlled trials of prophylactic anticoagulant therapy to reduce the incidence of TE and infection. This
in turn will help to improve the outcome in children with cancer.
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Cancer is the leading cause of disease-related death in
North American children [1,2]. Intensive therapy has
resulted in over 80% of cure-rates in children with cancer,
but therapy-related toxicity can limit the dose intensifica-
tion of chemotherapeutic agents and compromise the pro-
spect for cure [3]. Thus, it is important to minimize or
prevent therapy-related complications.
Thromboembolism (TE) is a common and potentially
fatal complication in children with cancer with up to
16% prevalence of symptomatic and ~ 40% of asymptom-
atic TE [4-10]. A recent population-based study showed
dramatic increase in the incidence of TE in hospitalized
children in the USA [4]. Cancer is a major underlying
disease in children with TE and accounts for ~ 40% of
pediatric TE [4-7]. We estimate that the risk of TE in
children with cancer is at least 600-times higher than
that in the general pediatric population [8-10].
TE is associated with significant morbidity, mortality
and financial burden. The majority of symptomatic TE in
children with acute lymphoblastic leukemia (ALL) occurs
in potentially fatal sites; ~ 50% in the central nervous sys-
tem (CNS) in the form of arterial ischemic stroke or sino-
venous thrombosis, 2% pulmonary embolism (PE) and 2%
in the right atrium [8,9]. A recent population based study
showed that children with cancer are at increased risk of
recurrent TE. Development of TE in children with cancer
also leads to prolonged hospitalization and increased mor-
tality [4]. The average case fatality ratio from TE in chil-
dren with ALL is reported to be 15% [8,9]. In addition, the
development of TE interferes with the scheduled therapy
and therapy interruptions are known to compromise cure
rates [10,11]. The estimated direct medical care cost of
adult TE in the USA is ~ $600 million/year [12]. Although
similar estimates are unavailable for children, develop-
ment of TE undoubtedly adds to the direct and indirect
therapy cost.
Thus, TE is a growing and significant problem in chil-
dren with cancer. TE can be treated with anticoagulant
therapy. Hence it is important to have reliable methods
for early diagnosis of TE. In addition, TE is preventable
with anticoagulant prophylaxis, even in children with
cancer [13,14]. To avoid mortality and morbidity related
to TE it is important to identify children at high risk for
development of TE. However, the risk factors predispos-
ing children with cancer to TE are yet to be defined.
Central venous line (CVL) is the single most important
risk factor for development of TE in children [15-29].
Long-term CVL has become an integral part of cancer-
therapy in children. It has improved both the quality of
care and quality of life in children with malignancy.
CVLs are commonly used to deliver chemotherapy,
blood products, parenteral nutrition and other intraven-
ous therapies as well as facilitate repeated blood drawingessential for the care of these patients. However, CVLs
are associated with significant complications leading to
morbidity and mortality [16-29]. Two recent studies
have identified a CVL-related complications rate of 40%-
46% in children with cancer [18,19]. Infection and TE
are the two most common and serious medical compli-
cations related to CVL and may necessitate CVL re-
moval in ~ 20%-35% of tunneled CVLs [29].
CVL-related TE is associated with significant acute
and chronic morbidity and mortality. Catheter occlusion
(in 11-40% patients), loss of venous access, infection
(22-40%), embolism to other vessels including PE (~13%),
and subsequent development of post-thrombotic syn-
drome (15-35%) are commonly described morbidities in
patients with CVL-associated TE [21,23,25,30]. As
observed in a recent study, patients with CVL-related TE
had shorter CVL life and increased number of CVLs com-
pared to those without TE [19]. Further, CVL-related
thrombi may promote TE at other sites in the body. In
addition, CVL-related acute morbidities lead to loss of
CVL and interruption of chemotherapy [19-31]. Using a
retrospective cohort design we and others have shown an
adverse impact of CVL dysfunction on survival of children
with cancer [32,33].Significance of CVL dysfunction
CVL-dysfunction (also known as occlusion or malfunc-
tion) is a common, but relatively less studied complica-
tion of CVL. Various studies defined dysfunction as the
inability to infuse fluids and/or withdraw blood and can
be mechanical or thrombotic [17,18,22,32,34]. The
thrombotic occlusion is thought to be resulting from
small clot at the tip or surrounding the tip of the CVL.
Dysfunction can be partial where infusion is possible but
blood cannot be aspirated or complete with inability to
either aspirate or infuse. In a prospective study of adults
with cancer, Lee et al., have documented 11% prevalence
of CVL-dysfunction; interestingly patients with CVL-
dysfunction had a significantly higher risk of developing
symptomatic CVL-related TE (OR 14.7, p<0.001) [34].
In comparison to adults, studies in children with can-
cer have reported much higher prevalence of CVL-
dysfunction ranging from 21%-39% [17,18,32,33,35].
Although, the higher prevalence of CVL-dysfunction
observed in these studies may be related to the smaller
sample size and retrospective study-design, physiologic-
ally, children are likely to be more susceptible for CVL-
dysfunction due to the smaller vascular dimensions and
higher CVL to vessel diameter ratio [35,36]. In fact the
observation of higher risk of CVL-related complications
in younger children supports this notion [17-20]. Three
retrospective studies (including ours) have evaluated the
risk of TE in children with cancer and CVL-dysfunction;
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of TE in children with CVL-dysfunction [17,32,33,36].
We propose a prospective, multicenter, cohort study
to evaluate the role of CVL-dysfunction as a predictor of
TE and to study the impact of CVL-dysfunction on the
frequency of infection and outcome of children with
cancer. We will also evaluate the impact of CVL-related
(type, insertion techniques and care guidelines) and
patient-related (age, height, body mass index) factors on
the incidence of CVL-dysfunction, TE and infection. We
plan to conduct this study in five tertiary care pediatric
oncology institutions. The participating institutions are
members of the Pediatric Oncology Group of Ontario
(POGO) and are responsible for the diagnosis and therapy
of all children with cancer in the province of Ontario.
The primary research question is as follows:
Do children with CVL dysfunction have increased risk
of symptomatic thromboembolism compared to those
without CVL dysfunction, while on cancer therapy?
Primary hypothesis
Children with CVL-dysfunction are at increased risk for
diagnosis of symptomatic TE while on therapy for cancer
compared to those without CVL-dysfunction.
Secondary hypotheses
1. Children with cancer and CVL-dysfunction have an
increased prevalence of infection compared to those
without CVL-dysfunction. Presence of both CVL-
dysfunction and infection increases the risk of TE in
children with cancer.
2. Children with cancer and CVL-dysfunction have
decreased OS and EFS compared to those without
CVL-dysfunction.
Aims
The overall objective of the study is to explore the rela-
tionship of CVL-dysfunction, TE and infection in
children with cancer and to study the impact of CVL-
dysfunction on overall outcome in children with cancer.
Primary aim
To compare the risk of symptomatic TE in children with
or without CVL-dysfunction while receiving therapy for
cancer.
Secondary aims
In children receiving therapy for cancer,
1. To compare the prevalence of infection at any site
in children with or without CVL-dysfunction
2. To compare the five-year OS and EFS in children
with or without CVL-dysfunction3. To delineate the relationship of CVL-dysfunction,
infection and TE
4. To evaluate the impact of different CVL-related
(type, insertion techniques, care guidelines) and
patient-related (age, height, body mass index) factors
on the development of CVL-dysfunction, TE and
infection
Study rationale
Rationale for primary aim
CVL-related TE in children is difficult to diagnose. CVL-
related TE could be symptomatic (with pain, edema, skin
discoloration and dilated veins) or asymptomatic [37,38].
The presence of symptoms reflects the site of obstruc-
tion, size of obstruction and acuteness of obstruction. In
children, especially in younger age group, the symptoms
of TE are difficult to detect. Hence even a significant TE
may go un-noticed. Journeycake et al., showed that only
5 of 21 children with CVL-related TE were symptomatic;
10 of 16 “asymptomatic” children had multiple CVL pla-
cements prior to the diagnoses of TE [17]. This observa-
tion highlights the importance of a reliable screening
method for diagnosis of CVL-related TE.
Although compression ultrasonography (USG) is the
diagnostic test of choice for suspected lower venous sys-
tem deep venous thrombosis (DVT), it has poor sensitiv-
ity for the diagnosis of DVT in the upper venous system
(central subclavian vein, brachiocephalic and superior
vena cava) [37,38]. Within the thoracic cage, the non-
compressibility of the vessel cannot be assessed due to
the bony ribs [39]. Prospective studies have shown that
bilateral venography is the most sensitive technique for
diagnosis of upper venous system TE within the thoracic
cage [37-40]. However, venography is an invasive, cum-
bersome and painful procedure, and it exposes children
to excessive radiation. Hence venography cannot be used
as a routine screening tool for evaluation of CVL-related
TE in children with cancer. Magnetic resonance venog-
raphy (MRV) is another non-invasive, safe and reliable
method to diagnose DVT. Although safe, MRV is very
costly, requires sedation or general anesthesia for
younger patients making it unsuitable for screening pur-
poses, and its sensitivity and specificity in children have
not been well defined [40]. Further, CVL-related small
clots such as fibrin sheath or ball valve thrombi (which
are mostly responsible for CVL-dysfunction) may not be
detected by USG or even linogram.
Thus, there is no reliable, safe, inexpensive and nonin-
vasive screening tool for diagnosis of CVL-related TE in
children. Hence one may have to consider surrogate mar-
kers as predictors of underlying TE. An ideal predictor
will reliably identify patients with high a probability of
underlying TE for whom evaluation by invasive tests will
be justified. Considering available evidence, we propose
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lying TE. If indeed the presence of CVL-dysfunction can
predict TE then such patients could be evaluated further
with the gold standard test of venography and treated
with anticoagulation therapy. This in turn will reduce the
risk of development of symptomatic TE and infection.
However, the first step is to confirm the presence (and
the strength) of association of CVL-dysfunction and TE
in a large prospective study.
Rationale for secondary aim 1
Bacterial and fungal infections and sepsis are well-known
complications in children undergoing intensive chemo-
therapy. Presence of CVL increases the risk of infections
[17-19,41-43]. Two recent prospective studies conducted
in children with cancer and hematological disorders
reported infection rates of 0.87 and 1.7/1000 catheter-days
[18,19]. In one study, 40% of patients had CVL-related infec-
tions and 44% of the episodes required CVL removal [43].
Although the association of CVL with infections has
been well documented, only recently investigators have
begun to explore the correlation of CVL-related infec-
tion with underlying local TE [42,43]. Prospective stud-
ies conducted in adult patients have shown that the local
or systemic CVL-related infections are likely to increase
the risk of TE in patients on therapy for cancer [42,43].
A retrospective study showed increased risk of throm-
bosis in children with cancer and documented infection
[odds ratio (OR) 2.2, p = 0.016] [17]. So far there is no
prospective study to evaluate the relationship of TE and
infection in children with cancer.
Rationale for secondary aim 2
Deitcher et al., reported CVL-dysfunction in 28% chil-
dren with brain tumors; children with CVL-dysfunction,
but not with major TE, had a reduced overall survival
[32]. Further, our results suggest that CVL-dysfunction
is an independent risk factor for poor OS and EFS in
children with cancer [33]. The poor outcome in children
with cancer and CVL-dysfunction could be related to
the interruption in therapy due to the loss of CVL or
due to the associated complications like TE and infec-
tion. In addition, CVL-dysfunction may represent activa-
tion of coagulation system; a marker of poor prognosis
in adults with cancer [32,33,36]. Thus, CVL-dysfunction
probably reflects significant underlying pathology. Des-
pite these observations there are so far no prospective
studies to evaluate the clinical significance of CVL-
dysfunction. Secondary aim 2 evaluates the relationship
of CVL-dysfunction with OS and EFS. CVL-dysfunction
may herald underlying undetected TE; the early diagno-
sis of which may prevent complications like overt TE,
infection and therapy-delays. This in turn will improve
the overall outcome in children with cancer.Rationale for secondary aim 3
Although the three common complications of CVL
namely CVL-dysfunction, infection and TE seem to be
closely associated, the exact relationship is unclear. One
retrospective study in children with cancer showed an
increased risk of TE in association with CVL-dysfunction
(OR 3.7, p = 0.001) and infection (OR 2.2, p = 0.016)
whereas children having both dysfunction and infection
had much higher risk of TE (OR 6.4, p<0.001) [17].
Presence of a local clot may lead to CVL-dysfunction as
well as may act as a nidus of infection providing fertile
ground for growth of the microorganisms. This may lead
to either local, CVL-related infection or infection else-
where in the body. CVL-dysfunction also needs frequent
manipulations such as repeated attempts to infuse or
withdraw blood; this may increase the chances of infection
in immunocompromised patients. On the other hand,
presence of infection can potentially initiate activation of
coagulation and formation of TE in the vessel which is
already damaged by CVL or by hyperosmolar infusions.
The small clot developed in the process may progress to
cause a significant TE either locally or distally elsewhere
in the body. This clot may also lead to CVL-dysfunction.
In summary, the cause and effect relationship of infec-
tion as well as the chronological relationship of infec-
tion, TE and CVL-dysfunction are still unclear. Figure 1
outlines our proposed hypothesis of the mechanism of
interaction of these three CVL-related complications.
Rationale for secondary aim 4
Currently there are no uniform, standard guidelines for
CVL insertion and care in children with cancer [44]. A
survey conducted by United Kingdom Children’s Cancer
Study Group showed that although 70%-80% of health
care professionals thought that the CVL-dysfunction and
TE were clinically important problems, there was re-
markable variation in the diagnosis, management and
prevention of CVL-dysfunction and TE [45]. There are
no guidelines for ideal flush solution, its concentration
or delivery schedule [23,44,45]. The CVL can be inserted
either by an interventional radiologist with percutaneous
technique or by the surgeons using cut-down technique.
Although for an occasional patient the practice may
vary, usually each institution has a consistent protocol
for CVL-insertion. We conducted a survey of all five
participating institutions evaluating the practice of CVL
insertion and the CVL-care guideline. This survey
showed that all the participating institutions use differ-
ent guidelines for the care of the long term CVLs. In
three of the five institutions usually surgeons insert the
CVLs and in two institutions the interventional radiologists
place the CVLs. By evaluating the impact of CVL- and
patient-related factors on development of TE, infection
and CVL-dysfunction as well as comparing the institutional
Thromboembolism CVL dysfunction
Infection
Infection is related to both CVL dysfunction and thrombosis
Small clot may lead to occlusion and dysfunction
Dysfunction may result from hypercoagulibilty with increase 
 risk of TE
Small clot causing dysfunction may act as
nidus of infection
Frequent manipulation of dysfunctional 
CVL may increase the risk of infection
Infection may stimulate local and/or 
systemic coagulation response resulting in 
occult or overt TE
Figure 1 Possible association of infection, CVL dysfunction and thrombosis.
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evidence-based guidelines for CVL-care.Methods and design
This is a prospective analytical cohort study conducted
at five tertiary care pediatric oncology centers in On-
tario. Figure 2 outlines the research design of the study.Justification for study design
Majority of children diagnosed with non-CNS cancer
have CVL placed for therapy. Since both TE and infec-
tion are complications of cancer-therapy, we have
chosen the best study design in observational method-
ology which is the prospective cohort study.Patient population
Children with non-CNS cancer diagnosed and treated at
five participating institutions.Patient eligibility
Inclusion criteria
All children (≤ 18 years of age) newly diagnosed with
non-CNS cancer will be eligible for the proposed study.
Not all patients with CNS cancers receive CVL and the
prevalence of TE in children with brain tumors is very
low (< 2%) [32,36,46]. Hence we will include only chil-
dren with non-CNS cancers.Exclusion criteria
1. Patients with relapsed cancer since they would have
had previous exposure to CVL
2. Age> 18 years at cancer diagnosis since majority are
treated at the adult facilities
3. Absence of CVL
4. Diagnosis of CVL-dysfunction prior to study enrollment
5. Patients on anticoagulation therapy or prophylaxis
6. Unable or unwilling to provide written informed
consent (and/or assent) for the proposed study
Observations
Dependent variables
1. Development of symptomatic TE in any location
while receiving therapy for cancer. Screening for
asymptomatic TE will not be performed.
2. Clinical or microbiologically proven infection as
defined below
3. Recurrence of cancer, second malignant neoplasm
(SMN) or death due to any cause
Independent variables
1. CVL-dysfunction as defined below
2. Age of the patient at the time of diagnosis of cancer
3. Type of cancer




New diagnosis of non-
CNS Cancer
Age ≤ 18 years
Eligible patients
Approach for consent (and assent, if indicated)
Study enrollment
















Figure 2 Flow diagram of the proposed study outlining the patient identification, study enrollment and follow up.
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1. CVL-dysfunction: Persistent or recurrent difficulty
in blood draw and/or infusion of at least one CVL
lumen with or without the need for instillation of
tissue plasminogen activator (tPA) documented on
two or more occasions. For a multi-lumen CVL,
difficulty in infusion or withdrawal of the same
lumen for ≥ 2 occasions is required to fulfill the
criteria of dysfunction.
2. Symptomatic thromboembolism: total or partial
occlusion of one or more vessels objectively
confirmed by at least one radiological diagnostic
method prompted by typical clinical symptoms.
CVL-related DVT: total or partial occlusion of vessel
in which CVL is placed and/or right atrial TE.
3. Infection: Published guidelines will be used for
diagnosis of CVL infection [47,48]. In addition a
patient will be diagnosed with infection in any of the
following situations:a. Septic shock requiring Pediatric Intensive Care
Unit (PICU) admission with or without
microbiological proof.
b. Positive blood culture collected from CVL and/or
peripheral vein requiring intravenous (IV)antibacterial and/or antifungal therapy beyond 48
hours.
c. Invasive fungal (including candidial) infection
defined as positive blood culture or positive
culture from any other site (except oral or
perianal candidiasis), radiological documented
probable infection requiring systemic antifungal
therapy and/or histopathological evidence of
fungal infection (e.g. documentation of fungal
hyphae on biopsy)
d. Clinically documented infection (e.g. CVL site
infection, tunnel track infection, cellulitis, abscess
formation at any site, typhlitis), with or without
microbiological proof, requiring antibacterial or
antifungal therapy beyond 48 hours. Minor
infections like suspected otitis media,
streptococcal throat infection will be excluded.
e. Persistent and/or recurrent fever of unknown
origin requiring antibiotics therapy beyond 7 days.
For the purpose of this study patients with
suspected or proven viral (e.g. influenza, chicken-
pox) as well as mycoplasma infection will not be
categorized as “infected”.
4. Event: recurrence of cancer, SMN or death due to
any cause.
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Newly diagnosed cancer patients will be identified
through pediatric oncology services at the participating
institutions. Study staff will review patients’ records to
determine eligibility for the proposed study. Eligible
patients will be approached, prior to CVL placement or
within two weeks of CVL placement, for informed con-
sent. Reasons for non-participation will be recorded for
all screened patients.
Study follow-up and study duration
This study will require no visits above and beyond those
required for the clinical care of the patient. After initial
hospitalization for evaluation and therapy for cancer, all
patients are seen frequently (either weekly or monthly)
at the outpatient clinics as part of their routine clinical
care. Patients will be monitored for infection, disease
progression or recurrence, or SMN. After completion of
therapy patients are followed life-long according to the
“After-Care-Guidelines” recommended by POGO.
Patient enrollment will occur until the required sample
size is achieved. We anticipate that the required patient
population will be enrolled during first two and half
years of the study. Patients will be followed for the de-
velopment of symptomatic TE until the completion of
cancer therapy and final removal of CVL which occurs
within 6–12 weeks post completion of therapy. There-
after overall outcome data regarding continued remis-
sion, recurrence of cancer, SMN or death will be
collected for each patient every six months for a total
period of five years from the initial diagnosis.
Ethical considerations
Patient safety and inconvenience This study will not
pose any additional risks to the patients. Only pertinent
data will be collected prospectively. No additional tests
will be performed and there will not be any change in
current institutional practice of CVL insertion, care or
management of complications.
Ethics This study is conducted in accordance with the
Ethical Conduct for Research Involving Humans out-
lined in Tri-Council Policy Statement [49]. The study
has been approved by the Research and Ethics Board
(REB) of McMaster University and Hamilton Health
Sciences as well as by the REB of each of the participat-
ing institution. Participation is fully voluntary after
informed consent either from the patient or the parent/
guardian as per the REB guidelines. In addition, assent
will be obtained from patients 7–15 years of age (or
younger if perceived competent to do so by physicians) as
per institutional guidelines. Participants are informed
about the nature of the study, their rights and obligationsand are assured that refusal to participate does not affect
patient care.
Confidentiality Procedures are developed to protect the
confidentiality of the data collected in accordance with
the REB’s requirements and Canadian privacy legislation.
All the data will be coded and stored securely to protect
individual confidentiality.
Patient care and benefit Patients with TE will be trea-
ted and counseled according to the recommended stand-
ard of care.
Data collection and analyses
Clinical data Will be collected and recorded for all
patients on standardized data collection form. In sum-
mary, data will include baseline patient characteristics,
personal and family history of TE or prothrombotic dis-
order; diagnosis of cancer and cancer-therapy, details of
CVL-dysfunction, details of infections and TE, if any,
and overall outcome from cancer.
Details of CVL insertion Details of CVL insertion (in-
cluding the date, body side, type of CVL used, type of
procedure, and any difficulty encountered) will be
recorded. For patients requiring more than one CVL
during the course of initial cancer therapy, details of
each additional CVL will be recorded separately. The life
span of the CVL will be measured in “catheter-days” cal-
culated from the time of insertion and time of removal
of CVL or the time of death or last follow-up if the CVL
was still in place.
Diagnosis, evaluation and management of patients
with symptomatic TE To ensure uniformity of diagno-
sis and evaluation, uniform guidelines for the definition
of symptomatic TE including clinical and radiological as-
sessment at the time of diagnosis of TE as published
elsewhere will be used. In addition, all patients diag-
nosed with symptomatic TE (either upper or lower limb
or elsewhere in the body) are recommended to undergo
bilateral upper venous system venography, contrast
enhanced MRV or computerized tomography (CT)
venogram to detect CVL-related TE. At the time of diag-
nosis of TE, laboratory evaluation will include CBC, co-
agulation profile (INR, APTT, D-dimer, fibrinogen) and
measurement of prothrombotic defects as per institu-
tional practice. Patients who develop a symptomatic TE
will be managed according to the institutional guide-
lines. Clinical, laboratory and radiological details as well
as management and outcome details of TE will be
recorded on the data collection form.
Halton et al. BMC Cancer 2012, 12:314 Page 8 of 11
http://www.biomedcentral.com/1471-2407/12/314Diagnosis, evaluation and management of patients
with infection Clinical and laboratory details of patients
fulfilling the definition of “infection” for this protocol
will be recorded. Patients with suspected or proven in-
fection will be managed according to the institutional
guidelines for the management of infection in an im-
munocompromised host.
Measurement of the exposure (i.e. CVL-dysfunction)
To avoid recall bias in recording CVL-dysfunction,
CVL-access information will be collected and recorded
prospectively. Currently on the the inpatient unit, every
time the CVL is accessed, the nurse accessing the CVL
completes the CVL checklist and records any problems
in blood-draw, infusion or need for tPA. Similar check-
list will be filled out for patients’ outpatient visits as well
as emergency room visits, if any. These checklists will be
collected and reviewed by the study staff at regular inter-
vals In addition, during the regular clinic visit patients
(or care givers) will be asked about the functioning of
CVL and any problems encountered and their responses
documented. We believe that combination of prospect-
ive documentation by nursing staff and patient recall will
capture all the events of CVL-dysfunction. The patient
will be categorized as “exposed” once the patient has
met the criteria for CVL-dysfunction.
Data documentation and retrieval All five participat-
ing institutions will use the CVL access and function
check list. Our research staff will train the health care
professionals for documentation and collection of pri-
mary and secondary outcome data. Data will be col-
lected in real time by chart review and review of
ancillary material (e.g. line function checklist).
Analysis plan The analysis and reporting of the study
will be performed in accordance with the STROBE
Statement [50]. The primary outcome is a binary
variable- symptomatic TE (presence/absence) as well as
a continuous variable (time to event). Independent vari-
ables include: age, number of catheter days and time to
CVL-dysfunction as continuous variables and, gender
(male/female), cancer type, CVL-dysfunction (presence/
absence), symptomatic TE (presence/absence), infection
(presence/absence) as categorical variables. The process
of participant recruitment and retention will be summar-
ized using a flow diagram. Analysis results of participant
recruitment and retention will be summarized using de-
scriptive summary measures: mean (standard deviation)
or median (minimum-maximum) for continuous vari-
ables; and number (percent) for categorical variables.
We will use logistic regression analysis to determine the
factors that can best discriminate between the two pa-
tient groups (i.e. those with and without TE). The list ofpotential factors is determined a priori and includes age
of the patient at the time of diagnosis of cancer, cancer
type; CVL-dysfunction (presence/absence), infection
(presence/absence) and CVL type (internal/external).
Univariate analyses will be performed to determine
which variables to include in the multivariable models
using the criterion of alpha = 0.20. Initially, we will use
complete case analysis (i.e. do the analysis without tak-
ing missing data into account) and then repeat the ana-
lyses with missing data handled by multiple imputation
technique [51-53].
For regression models, we will report the OR (for lo-
gistic regression), corresponding standard error, 95%
confidence intervals and associated p-values. We will re-
port P-values to 3 decimal places with p-values less than
0.001 reported as p<0.001. For all tests, we will use
alpha =0.05 level of significance. Examination of resi-
duals will provide an assessment of model assumptions
for regression analyses. Goodnees-of-fit for the models
will be performed using appropriate Hosmer-Lemeshov
tests. For multivariable regression analysis, we anticipate
multicolinearity [54]. We will assess colinearity using the
variance inflation factor (VIF) which measures the extent
to which the variance of the model coefficients will be
inflated (because of the correlation of the variable with
other predictor variables) if that variable is included in
the model. Variables with VIF >10 will be considered
colinear and will be excluded from the analysis [55].
The discriminant performance of the model will be
evaluated using sensitivity, specificity and the area under
the ROC – receiver operating characteristic curve. We
will use bootstrapping approach to internally validate
the model. We will compare the performance character-
istics (i.e. sensitivity, specificity, area under the ROC
curve, etc) between the original model and the bootstrap
model. OS and EFS will be estimated using Cox-
regression which will allow for adjustment of confound-
ing variables. Hazard ratio (HR) will be calculated using
log-rank method.
Sample size The primary objectives of the study are to
develop a model to discriminate between patients with
and without symptomatic TE. To determine the optimal
discriminant clinical model we will undertake a multi-
variable analysis. Simulation studies demonstrate that lo-
gistic models require 10 to 15 events per predictor to
produce stable model estimates [54,55]. Based on our
retrospective data and published reports we anticipate
that at least 20% patients will be exposed (i.e. with CVL
dysfunction) and 80% unexposed (i.e. without CVL dys-
function) [17,33,36]. Preliminary data from the retro-
spective study showed that the overall prevalence of TE
was 11%; 23% of exposed and 9% of unexposed patients
had TE. We will evaluate five predictors in our
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sample size of 450 patients (90 exposed with CVL dys-
function; and 360 without CVL dysfunction). The overall
rate of symptomatic TE is assumed to be 11% (~50
events of TE) [36].
Discussion
To our knowledge, this is the first prospective and com-
prehensive evaluation of CVL-dysfunction in pediatric
oncology. This study will improve our knowledge
regarding the mechanism of CVL-dysfunction and the
relationship amongst CVL-dysfunction, infection and TE
in children with cancer. Most importantly this study will
evaluate the impact of CVL-dysfunction on the develop-
ment of TE, infection and overall outcome from cancer
in children.
TE is a growing and significant problem in children
with cancer. TE can be treated with anticoagulant ther-
apy. Hence it is important to have reliable methods for
early diagnosis of TE. In addition, TE is preventable with
anticoagulant prophylaxis [13,14]. However, children
with cancer are also at risk of bleeding from
thrombocytopenia and other effects of treatment. Chil-
dren with cancer receiving anticoagulation therapy or
prophylaxis are shown to have 5-15% bleeding risk
[9,10,56]. Ideally, thromboprophylaxis is offered only to
those patients with high risk of thrombosis and low or
acceptable risk of bleeding. Thus, for judicious use of
thromboprophylaxis, identifying a population at high
risk for TE is of paramount importance. The proposed
study aims to identify predictors of TE in children with
cancer.
If we confirm our primary hypothesis then we can use
CVL-dysfunction as a predictor of TE and will be able
to identify children at high risk for TE. Based on the
results of this study we will design future studies for
earlier diagnosis of TE using definitive methods like ven-
ography and future randomized controlled trial of
prophylactic anticoagulant therapy in children with can-
cer. This will ultimately help to reduce the incidence of
TE and its impact on overall outcome as well as quality
of life in children undergoing treatment for cancer.
If we confirm the association of CVL-dysfunction, TE
and infection, then we can identify children at high risk
for infection (a major complication in children with can-
cer) and institute prophylactic strategies aimed at redu-
cing dysfunction and infection (e.g. anticoagulation
therapy).
In addition, this study will compare the practices of
CVL insertion and care across five pediatric tertiary care
centers in Ontario. Although each institution has based
their practices on internal quality control studies, there
are so far no data comparing or evaluating different
practices across the Province in large patient population.This study will allow us to evaluate the impact of institu-
tional practices of CVL insertion and care on the devel-
opment of CVL-related complications. This will help to
develop evidenced based guidelines for CVL insertion
and care.
Strengths and potential limitations of the study
The major strength of the study is the use of a prospective
cohort design. Previous studies were single institution
studies using retrospective design [17,32,33,36]. These
studies report up to 30% of missing data [17,32,33,36]. To
avoid this problem we will use uniform data collection
forms for all study participants and for patients with TE
which is likely to capture all the relevant information. Fur-
ther, the CVL access data will be collected prospectively
and hence the exposure criteria will be recorded properly
avoiding any recall bias.
Unlike previous studies, evaluation of CVL-
dysfunction is the primary aim of our study which
formed the basis of our sample size calculation. By in-
clusion of only symptomatic and objectively confirmed
TE, we will avoid ambiguity over diagnosis, and thus,
reporting of TE. Uniform guidelines for diagnosis and
evaluation will likely minimize chances of misdiagnosis
of TE.
In addition the following steps are taken to minimize
sources of errors and likely biases improving internal
validity of the study. To avoid selection bias all consecu-
tive newly diagnosed non-CNS cancer patients meeting
the inclusion criteria will be eligible and approached for
participation in the proposed study. All reported events
of TE will be confirmed by an independent adjudication
committee. To avoid recall bias CVL access data will be
collected prospectively and hence the exposure criteria
will be recorded properly. Assessors (radiologists) evalu-
ating for TE will be blinded as regards the “exposure”
status to avoid measurement bias. With the use of uni-
form data collection forms for all study participants and
patients with TE, infection and CVL dysfunction, all the
relevant information is likely to be captured. Further, all
data will be analyzed centrally.
Another strength of the study is that this study is con-
ducted across five pediatric oncology institutions with
inclusion of wide range of cancer diagnoses. Hence we
think that the findings of the study will be generalizable
to pediatric oncology population. The results of this
study will also be applicable for adults with cancer as
well as to the population of patients with other chronic
diseases who need long term CVL.
The main limitation is that we will not be screening
for asymptomatic TE. However, the significance of
asymptomatic TE detected by screening method is un-
known. In addition, children with cancer have an
increased risk of TE throughout the cancer-therapy
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[17,27,31,36]. The large amount of data collection could
be perceived as a limitation of this study. However, this
will allow us to evaluate various variables.
In summary, use of CVL has improved the quality of
life and care in children with cancer. However, CVL is
associated with significant complications namely CVL-
dysfunction, TE and infection. This study aims to
identify the relationship of these three CVL-related com-
plications and evaluates the role of CVL-dysfunction as
a predictor of TE in children with cancer. This study will
also prospectively evaluate the impact of CVL-dysfunction
on the outcome from cancer. The results of this study in
turn will help to identify children at high risk for TE and
to develop preventive strategies for both infection and
thrombosis. This, we believe, will improve overall out-
come of children with cancer.
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